525 related articles for article (PubMed ID: 23553147)
1. Improvement in the detection of locoregional recurrence in head and neck malignancies: F-18 fluorodeoxyglucose-positron emission tomography/computed tomography compared to high-resolution contrast-enhanced computed tomography and endoscopic examination.
Rangaswamy B; Fardanesh MR; Genden EM; Park EE; Fatterpekar G; Patel Z; Kim J; Som PM; Kostakoglu L
Laryngoscope; 2013 Nov; 123(11):2664-9. PubMed ID: 23553147
[TBL] [Abstract][Full Text] [Related]
2. Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck.
Kostakoglu L; Fardanesh R; Posner M; Som P; Rao S; Park E; Doucette J; Stein EG; Gupta V; Misiukiewicz K; Genden E
Oncologist; 2013; 18(10):1108-17. PubMed ID: 24037978
[TBL] [Abstract][Full Text] [Related]
3. Use of Diffusion-Weighted Imaging and
Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
[TBL] [Abstract][Full Text] [Related]
5. Preoperative Contrast-Enhanced CT Versus ¹⁸F-FDG PET/CT Evaluation and the Prognostic Value of Extranodal Extension for Surgical Patients with Head and Neck Squamous Cell Carcinoma.
Lee JR; Choi YJ; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1020-7. PubMed ID: 26122372
[TBL] [Abstract][Full Text] [Related]
6. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer).
Seo YL; Yoon DY; Baek S; Ku YJ; Rho YS; Chung EJ; Koh SH
Eur Radiol; 2012 Oct; 22(10):2246-54. PubMed ID: 22562091
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma.
Yi JS; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY; Roh JL
J Surg Oncol; 2012 Nov; 106(6):708-12. PubMed ID: 22674652
[TBL] [Abstract][Full Text] [Related]
8. Detection of loco-regional recurrence in malignant head and neck tumors: a comparison of CT, MRI, and FDG PET-CT.
Kim ES; Yoon DY; Moon JY; Baek S; Han YM; Seo YL; Yun EJ
Acta Radiol; 2019 Feb; 60(2):186-195. PubMed ID: 29754496
[TBL] [Abstract][Full Text] [Related]
9. Comparison of diffusion-weighted MR imaging and
Schroeder C; Lee JH; Tetzner U; Seidel S; Kim SY
Eur J Radiol; 2020 Sep; 130():109157. PubMed ID: 32652403
[TBL] [Abstract][Full Text] [Related]
10. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
[TBL] [Abstract][Full Text] [Related]
11. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
14. Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
Dejaco D; Uprimny C; Widmann G; Riedl D; Moser P; Arnold C; Steinbichler TB; Kofler B; Schartinger VH; Virgolini I; Riechelmann H
Cancer Imaging; 2020 Sep; 20(1):69. PubMed ID: 32993805
[TBL] [Abstract][Full Text] [Related]
15. Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.
Slevin F; Subesinghe M; Ramasamy S; Sen M; Scarsbrook AF; Prestwich RJ
Br J Radiol; 2015 Aug; 88(1052):20140592. PubMed ID: 26081447
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma.
Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Br J Cancer; 2013 Dec; 109(12):2973-9. PubMed ID: 24149172
[TBL] [Abstract][Full Text] [Related]
17.
Han EJ; O JH; Yoo IR; Kim YS; Kim MS; Kang JH; Choi WH
Hell J Nucl Med; 2017; 20(2):134-140. PubMed ID: 28697190
[TBL] [Abstract][Full Text] [Related]
18.
Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
